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Abstract 1 
Hematopoietic stem and progenitor cell (HSPC) formation and lineage differentiation involve 2 
gene expression programs orchestrated by transcription factors and epigenetic regulators. 3 
Genetic disruption of the chromatin remodeler chromodomain-helicase-DNA-binding protein 7 4 
(CHD7) expanded phenotypic HSPCs, erythroid, and myeloid lineages in zebrafish and mouse 5 
embryos. CHD7 acts to suppress hematopoietic differentiation. Binding motifs for RUNX and 6 
other hematopoietic transcription factors are enriched at sites occupied by CHD7 and 7 
decreased RUNX1 occupancy correlated with loss of CHD7 localization. CHD7 physically 8 
interacts with RUNX1 and suppresses RUNX1-induced expansion of HSPCs during 9 
development through modulation of RUNX1 activity. Consequently, the RUNX1:CHD7 axis 10 
provides proper timing and function of HSPCs as they emerge during hematopoietic 11 
development or mature in adults, representing a distinct and evolutionarily conserved control 12 
mechanism to ensure accurate hematopoietic lineage differentiation. 13 
 14 
Significance  15 
Hematopoiesis involves the control of gene expression that regulates the processes of 16 
proliferation and differentiation.  We found that the chromatin remodeler CHD7 controls the 17 
differentiation process.  Knockdown or knockout of CHD7 leads to enhanced hematopoietic 18 
differentiation in zebrafish and mice, suggesting that CHD7 acts as a brake on gene expression 19 




Hematopoiesis is established in three waves at different anatomic sites in all vertebrate 24 
embryos. The first, primitive wave takes place in the yolk sac and generates primitive 25 
 5 
erythrocytes, macrophages and megakaryocytes. In the second, definitive wave, hematopoietic 26 
progenitor cells (HPCs) differentiate from hemogenic endothelium in the yolk sac and dorsal 27 
aorta (1), and in the placenta, vitelline, and umbilical arteries in mice and humans (2). The third 28 
wave, also derived from hemogenic endothelium in the dorsal aorta, vitelline and umbilical 29 
arteries, produces hematopoietic stem cells (HSCs).  30 
A large-scale in vivo reverse genetic screen targeting zebrafish homologs of 425 human 31 
chromatin factors with antisense oligonucleotide morpholinos to identify genes controlling 32 
embryonic hematopoietic stem and progenitor cell (HSPC) formation uncovered chromodomain-33 
helicase-DNA-binding protein 7 (Chd7) as the only factor that increased the expression of both 34 
primitive and definitive hematopoietic genes, including runx1, when inhibited (3). The CHD class 35 
of ATP-dependent chromatin remodeling enzymes alters nucleosome structure and has been 36 
implicated in the maintenance of mouse embryonic stem cells, mammalian development, DNA 37 
damage response, and transcription regulation (4). Autosomal dominant CHD7 mutations cause 38 
the inherited CHARGE and Kallmann syndromes (5). Mutations and copy number variations of 39 
CHD7 have been found in hematologic and other cancers (6).  40 
RUNX1 is a master transcription factor absolutely required for hemogenic endothelial 41 
specification and the endothelial to hematopoietic cell transition in zebrafish and mice (7-12). 42 
Loss of RUNX1 in adult HSCs results in HPC and myeloid lineage expansion and lymphoid 43 
lineage depletion (13). Here, we show that CHD7 genetically interacts with RUNX1 during 44 
hematopoietic ontogeny and adult hematopoiesis, and disruption of CHD7 leads to enhanced 45 







CHD7 negatively regulates hematopoietic development. 52 
Morpholino (MO) knockdown of chd7 in zebrafish embryos (chd7 morphants) increased 53 
the expression of primitive erythroid-specific -globin e3 (hbbe3) at 17 hours post-fertilization 54 
(hpf), and definitive hematopoietic markers myb and runx1 in the dorsal aorta (DA) at 36 hpf (SI 55 
Appendix, Fig. S1A-D). Markers of hematopoietic mesoderm at 10-12 hpf (tal1 and lmo2) were 56 
elevated in chd7 morphants, while earlier expression of the pan-mesodermal markers ntla and 57 
eve1, and the early hematopoietic marker drl at 6 hpf were normal (Fig. 1A and SI Appendix, 58 
Fig. S2A). Markers of primitive erythroid (gata1, gata2, hbbe3) and myeloid cells (mpx and 59 
spi1b) were increased in the posterior lateral mesoderm, and expression of definitive myeloid 60 
(myb) and erythroid (hbae1, hbbe1) markers were elevated in the caudal hematopoietic tissue 61 
(CHT), a site of HSPC colonization (Fig. 1A,B and SI Appendix, Fig. S2A). Expression of 62 
endothelial kdrl was normal, and analysis of Tg(kdrl:EGFP) chd7 morphants showed no 63 
increase in GFP+ endothelial cells (SI Appendix, Fig. S1E,F). Hence, chd7 regulates both 64 
primitive and definitive hematopoietic lineage gene expression in the zebrafish embryo. The 65 
increased expression of hematopoietic genes correlated with enhanced hematopoiesis.   chd7 66 
Tg(myb:EGFP) morphants had 1.6-fold more myb:EGFP+ cells in the DA and 2.8-fold more in 67 
the posterior tail region than control embryos (Fig. 1C). Similar increases were observed in two 68 
other hematopoietic transgenic lines, Tg(lmo2:DsRed) and Tg(itga2b:EGFP) (SI Appendix, Fig. 69 
S1G), and in an independent study (14). We confirmed a reduction of rag1 expression in the 70 
thymus indicative of a decrease in T lymphocyte progenitors (SI Appendix, Fig. S2A), which was 71 
attributed in a previous study to severely impaired thymus organogenesis (14). We conclude 72 
that chd7 negatively regulates HSPC formation in the zebrafish embryo. 73 
 74 
To determine if the function of CHD7 in hematopoiesis is conserved in the mouse, we 75 
measured the number of phenotypic HSPCs in the aorta-gonad-mesonephros (AGM) region 76 
 7 
of Chd7 mutant embryos. HSPCs in mouse embryos briefly accumulate as clusters of 77 
Runx1+CD31+Kit+ cells attached to luminal endothelial cells in the major caudal arteries, 78 
peaking in number at embryonic day (E) 10.5 (15). Germline deletion of CHD7 caused a 79 
developmental delay by E10.5 and lethality by E11.5 (16), preventing accurate assessment of 80 
AGM hematopoiesis in null embryos. Therefore, we enumerated Runx1+CD31+Kit+ 81 
hematopoietic cluster cells in Chd7+/- embryos, which are viable, and in embryos with Chd7f 82 
alleles deleted by Cre driven by vascular endothelial cadherin (Cdh5) regulatory sequences 83 
(Cdh5-Cre) (SI Appendix, Fig. S3A). There was a significant increase in Runx1+CD31+Kit+ 84 
cells in the AGM region of Chd7f/f;Cdh5-Cre embryos and a trend towards increased numbers 85 
in Chd7+/- embryos (Fig. 1D,E). The numbers of definitive erythroid and myeloid progenitors in 86 
the yolk sac of mutant embryos were also increased (Fig. 1F), but lymphoid progenitor 87 
numbers in the AGM, umbilical and vitelline arteries (A+U+V) were lower (Fig. 1G). The 88 
number of primitive erythroid progenitors in the yolk sac was not altered (Fig. 1H). We 89 
conclude that CHD7 restrains the numbers of definitive erythroid and myeloid progenitors 90 
differentiating from the yolk sac and phenotypic HSPCs in the AGM region in both zebrafish 91 
and mouse embryos. 92 
 93 
CHD7 functions to regulate myeloid output from HSCs. 94 
 We evaluated the hematopoietic function of CHD7 in the mouse by excising Chd7f 95 
alleles with Vav1-Cre (SI Appendix, Fig. S3A,B). CHD7 is most highly expressed in long term 96 
repopulating HSCs (LT-HSCs) (SI Appendix, Fig. S3C), but deletion of CHD7 did not 97 
significantly affect the percentages of phenotypic LT-HSCs (CD48-CD150+ lineage-Sca1+Kit+ 98 
(LSK)) or restricted hematopoietic progenitors (HPC-1, CD48+CD150-LSK), although there was 99 
a significant increase in CD48-CD150- LSK cells,  which contain several populations of 100 
multipotent progenitors (MPPs) (17) (Fig. 2A). The frequency of functional CHD7 deficient LT-101 
HSCs in both whole BM and in purified CD48-CD150+LSK cells, determined by limiting dilution 102 
 8 
transplants, was increased >2-fold when donor contribution to Mac1+ peripheral blood (PB) cells 103 
was scored (Fig. 2B,C). In contrast, no significant increase in LT-HSC frequency was detected 104 
when donor contribution to CD48-CD150+LSK cells in the recipient BM was scored (SI 105 
Appendix, Fig. S3D), suggesting that CHD7 does not affect the frequency of LT-HSCs, but 106 
constrains the myeloid lineage output of LT-HSCs and potentially other downstream 107 
progenitors. Serial transplantation of BM cells revealed no differences between control and 108 
CHD7 deficient HSCs by the fourth transplant, thus CHD7 deficient LT-HSCs had normal self-109 
renewal capacity (SI Appendix, Fig. S3E,F). There were no differences in proliferation, 110 
quiescence, or apoptosis between CHD7 deficient and control LT-HSCs, MPPs, or HPC-1s in 111 
adult mice (SI Appendix, Fig. S3G-I). The frequencies of phenotypic LT-HSCs and HPC-1s were 112 
not differentially affected by stress induced by 5-fluorouracil injection (SI Appendix, Fig. S3J). 113 
We conclude that CHD7 loss does not negatively impact most functional properties of LT-HSCs. 114 
 115 
Gene expression profiling did, however, reveal differences between control and CHD7 116 
deficient LT-HSCs. Ingenuity Pathway Analysis determined that genes upregulated in CHD7 117 
deficient LT-HSCs were significantly associated with hematopoietic system development and 118 
function, immune cell trafficking, cell to cell signaling and interaction, and cellular movement 119 
(Fig. 2D and Supplementary Dataset 1,2). Genes representative of each blood lineage, 120 
including erythroid (Hbb-b1, glycophorins), myeloid (Mpo, Lyz1, Alox5), and lymphoid (Thy1) 121 
were upregulated in CHD7 deficient LT-HSCs (Fig. 2E, Supplementary Dataset 1), suggesting 122 
that CHD7 deficiency results in LT-HSCs that are more primed for multilineage differentiation. 123 
Additional evidence that CHD7 constrains myeloid lineage differentiation include an elevated 124 
frequency of differentiated Gr1+Mac1+ cells in the liver of E14.5 Chd7+/- fetuses (SI Appendix, 125 
Fig. S4A) and in adult BM and spleen of Chd7f/f;Vav1-Cre mice (SI Appendix, Fig. S4B), and 126 
increased numbers of granulocyte/monocyte progenitors in culture (SI Appendix, Fig. S4C). We 127 
 9 
conclude that CHD7 deficient LT-HSCs are more primed for differentiation, particularly of 128 
myeloid lineage cells. 129 
 130 
CHD7 cooperates with the RUNX1 transcription factor. 131 
To determine how CHD7 regulates hematopoietic genes, we performed chromatin 132 
immunoprecipitation followed by sequencing (ChIP-seq) to identify CHD7 occupied loci in the 133 
murine 416B HPC line (18) (Supplementary Dataset 3). CHD7-occupied gene regions are 134 
DNaseI hypersensitive and co-localize with multiple hematopoietic transcription factors (19) 135 
(Fig. 3A-D). Ets, Runx, and Gata motifs were enriched at CHD7 bound sites, suggesting that 136 
CHD7 functions in part through key hematopoietic transcription factors to regulate 137 
hematopoiesis (Fig. 3E). Given that RUNX1 was shown to interact with CHD7 (20), we 138 
performed ChIP-seq to determine if RUNX1 influenced CHD7 occupancy. We were unable to 139 
generate a RUNX1 deficient HPC line, so instead used a Tet-inducible, neomorphic CBFB-140 
MYH11 fusion gene to block RUNX1 activity (SI Appendix, Fig. S5A). CBF-SMMHC (encoded 141 
by CBFB-MYH11) blocks RUNX1 activity, in part, by sequestering it off the DNA (21). Upon 142 
induction of CBFB-MYH11 expression (+Dox), we identified peaks with >4-fold decreases in 143 
RUNX1 binding (Fig. 3F and SI Appendix, Fig. S5B). Of the 3,036 peaks that lost RUNX1 144 
binding, 1,043 (34.4%) showed >2-fold and 270 (8.9%) >4-fold loss in CHD7 binding (Fig. 3F 145 
ii,iii), as illustrated for the Evi5 gene (Fig. 3G). In contrast, of the 10,045 RUNX1 peaks that did 146 
not decrease upon CBFB-MYH11 expression, only 781 (7.8%) showed >2-fold and 65 (0.6%) 147 
>4-fold CHD7 binding loss (Fig. 3F ii,iv). These results are reproducible and indicate that CHD7 148 
is selectively lost from regions of the genome where RUNX1 binding is attenuated 149 
(Supplementary Dataset 4). This observation is supported by short-term analysis of 150 
CRISPR/Cas9 knockouts for CHD7 and RUNX1 in which initial gene expression changes when 151 
either gene is perturbed are positively correlated (SI Appendix, Fig. S5C and Supplementary 152 
Dataset 5), and consistent with previous data showing that ~30% of genes that are differentially 153 
 10 
expressed in CBFB-MYH11-expressing cells upon CHD7 loss are direct RUNX1 targets (20). 154 
Consequently, CHD7 and RUNX1 function together on target genes important for 155 
hematopoiesis in HPCs at the genomic level.  156 
 157 
CHD7 physically interacts with RUNX1. 158 
We independently identified CHD7 in an unbiased mass spectrometry screen for 159 
proteins that interact with RUNX1 and its non-DNA binding partner CBF (Fig. 4A and Table 160 
S1). We and others confirmed the interaction of endogenous CHD7 with RUNX1 and CBF by 161 
co-immunoprecipitation in a cell line that expresses high levels of all three proteins (20) (Fig. 162 
4B). CHD7 binds the activation domain of RUNX1, as RUNX1 proteins with deletions impinging 163 
on the activation domain do not immunoprecipitate CHD7 (Fig. 4C-E). Thus, the RUNX1 164 
activation domain, which is essential for RUNX1 function (22), mediates the interaction with 165 
CHD7. 166 
 167 
We functionally mapped domains in CHD7 responsible for its ability to constrain definitive 168 
hematopoiesis. Overexpression of human CHD7 (hCHD7) mRNA (23) suppresses HPCs in the 169 
CHT of zebrafish embryos (Fig. 4F). We injected five different hCHD7 truncation mutants (24) 170 
into zebrafish embryos to determine which mutant (mut) proteins could suppress myb/runx1 171 
expression. Only hCHD7 mut 5 lacking the N-terminal portion of the ATPase/helicase domain 172 
failed to suppress myb/runx1 expression, whereas deletion of the chromodomains (mut 6) or the 173 
SLIDE/SANT/BRK domains (mut 2-4) had no effect (Fig. 4G,H, SI Appendix, Fig. S2B). The 174 
catalytically dead mutant (23) hCHD7K999R also failed to suppress myb expression in the CHT 175 
(Fig. 4F,  Appendix, Fig. S2B). The ability of CHD7 to suppress hematopoiesis requires its 176 
ATPase/helicase activity. 177 
 178 
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CHD7 genetically interacts with RUNX1 to regulate hematopoiesis. 179 
We tested if CHD7 and RUNX1 genetically interact. We observed an increased 180 
percentage of Gr1+Mac1+ cells in the spleen of Runx1+/-;Chd7+/- compared to Chd7+/- mice, 181 
suggesting that CHD7 represses adult myelopoiesis in collaboration with RUNX1 (Fig. 5A). We 182 
also identified a genetic interaction during embryonic hematopoiesis. In the absence of RUNX1, 183 
primitive erythropoiesis in the murine yolk sac is delayed, as evidenced by an increase in 184 
immature Ter119loKit- cells and a commensurate decrease in mature Ter119hiKit- cells (Fig. 185 
5B,C). This delay is more pronounced in embryos heterozygous for the neomorphic Cbfb-186 
MYH11 allele (Cbfb+/M) (Fig. 5C). The dominant negative effect of the CbfbM allele requires 187 
RUNX1, as it is suppressed by RUNX1 deficiency (Cbfb+/M;Runx1-/-) (25) (Fig. 5B). Deletion of 188 
either one or both Chd7 alleles (Chd7+/- or Chd7-/-) did not alter the percentages of Ter119loKit- 189 
and Ter119hiKit- cells, but in Cbfb+/M embryos, loss of Chd7 partially restored primitive 190 
erythrocyte differentiation (Fig. 5B,C). Since either loss of Runx1 or Chd7 can suppress the 191 
CbfbM allele, they both function in the same genetic pathway and are required for the 192 
neomorphic activity of the CBFB-MYH11 fusion gene. This is consistent with a previous study 193 
showing loss of CHD7 delays leukemogenesis caused by CBFB-MYH11 (20). 194 
 195 
We also examined the functional relationship between chd7 and runx1 during embryonic 196 
hematopoiesis in the zebrafish. Definitive hematopoiesis in the DA of zebrafish embryos is 197 
impaired by a runx1w84x mutation that truncates the Runx1 protein (26). Knockdown of chd7 in 198 
runx1w84x/w84x embryos did not restore myb expression in the DA, as runx1 is necessary for 199 
HSPC development, myb expression, and CHD7 activity (Fig. 5D). Therefore, we tested the 200 
effect of runx1 overexpression on CHD7 activity. Ectopic expression of hCHD7 mRNA 201 
decreases myb expression in the CHT, while overexpression of runx1 from an inducible heat 202 
shock promoter increases myb mRNA levels as expected (Fig. 5E). When hCHD7 mRNA was 203 
 12 
expressed in the context of heat shock induced runx1, the ability of runx1 to increase myb 204 
expression was suppressed (Fig. 5E). Altogether, the data indicate that chd7 functions to inhibit  205 




Discussion  210 
We uncovered a novel mechanism in hematopoietic differentiation in which the activity of 211 
the key transcription factor RUNX1 is regulated by the chromatin-remodeling enzyme CHD7. 212 
Expression of CHD7 is not blood specific; nonetheless it functions to negatively regulate several 213 
stages of embryonic and adult hematopoiesis that are well conserved from zebrafish to mouse. 214 
Loss of CHD7 enhances HSPC formation and lineage differentiation, particularly of the myeloid 215 
lineage. In adult mice, CHD7 deficient LT-HSCs have a gene expression profile suggestive of a 216 
primed state that promotes multilineage differentiation, indicating that the enhanced myeloid cell 217 
contribution originates from the LT-HSC. Genomic analysis of CHD7 occupancy suggests that it 218 
can cooperate with multiple hematopoietic transcription factor genes. Here, we demonstrate that 219 
CHD7 genetically and physically interacts with RUNX1 through the RUNX1 transactivation 220 
domain, and that RUNX1 recruits CHD7 to a subset of its target genes. The outcome of the 221 
interaction between RUNX1 and CHD7 depends on the developmental context. RUNX1 and 222 
CHD7 have opposing effects during HSPC formation from hemogenic endothelium, with RUNX1 223 
promoting and CHD7 dampening the process. In the adult, however, RUNX1 and CHD7 both 224 
function to restrict myeloid lineage output from LT-HSCs (27, 28). This may have more to do 225 
with RUNX1’s opposing functions in determining myeloid progenitor numbers in the embryo 226 
versus the adult, as we show here that in multiple contexts, in zebrafish embryos, mouse 227 
embryos, and adult mice, CHD7 appears to constrain the differentiation of myeloid lineage cells.  228 
 13 
Distinct functions and mechanisms for CHD7 have been described in different cell types 229 
and developmental stages. In murine ES cells, CHD7 is associated with active chromatin and 230 
actively transcribed genes, yet its dominant activity is to suppress gene expression (29). In 231 
contrast, CHD7 primarily augments gene expression in pre-leukemic HSPCs expressing the 232 
CBFB-MYH11 protein (20). CHD7’s function in embryonic and adult hematopoiesis is similar to 233 
what has been observed in ES cells, i.e. that it primarily dampens the expression of actively 234 
transcribed genes.  235 
 236 
 Mutational analysis showed that the catalytic activity of the ATPase/helicase domain is 237 
required for CHD7 to suppress myb expression in zebrafish embryos. Other domains such as 238 
the chromodomains and SANT domain, which are required for CHD7’s ATPase/helicase activity 239 
in vitro and are mutated in CHARGE syndrome (24), were not required to repress embryonic 240 
hematopoiesis. A possible explanation for this paradox is overexpression of CHD7 lacking 241 
chromodomains or the SANT domain may bypass the stricter requirement for these domains in 242 
biochemical assays using purified proteins, or in vivo where CHD7 is present at physiological 243 
levels. ATP binding may be necessary for the ATPase/helicase domain to interact with other 244 
proteins.  An example of this is the RNA helicase UAP56, which must bind ATP to interact with 245 
U2AF in spliceosome assembly (30). Five proteins detected in our CHD7 pulldown are known to 246 
be part of, or interact with, the Mi-2/NuRD repressive complex, thus loss of ATP binding by 247 
CHD7 could impair the recruitment of repressors at enhancers or gene bodies to regulate gene 248 
transcription, leading to increased expression of RUNX1 and other hematopoietic transcription 249 
factor targets. A third possibility is there may be multiple ways by which CHD7 is recruited to 250 
chromatin and catalysis is activated; in developmental hematopoiesis proteins such as RUNX1 251 
may substitute for the chromodomains and SANT domain to recruit CHD7 to chromatin and 252 
stimulate its enzymatic activity. Future work elucidating the molecular mechanism of how CHD7 253 
navigates the chromatin to regulate transcription will provide additional insights into how 254 
 14 
epigenetic regulators function with transcription factors to promote appropriate lineage 255 
differentiation.  256 
 257 
 258 
Materials and Methods 259 
Animal models. 260 
Zebrafish (Danio rerio) Tüebingen strain were bred and maintained according to 261 
institutional animal care and use committee guidelines at Boston Children’s Hospital. 262 
Morpholino sequences were: chd7 exon 3: ACTCGTTTATACTCTACACGTACCT; chd7 exon 4: 263 
TTACAAGCAAGTTTACCTGAAC ACC (Gene Tools, LLC). Chd7 morpholinos were 264 
resuspended in nuclease-free water, and equal amounts of each morpholino were combined 265 
(12-15ng) for microinjection at the single cell stage. Standard control morpholino from Gene 266 
Tools was used. Fish lines Tg(myb:EGFP), Tg(lmo2:dsRed), Tg(itga2b:EGFP, Tg(kdrl:RFP), 267 
Tg(kdrl:EGFP), Tg(hsp70:runx1;cmlc:dsRed), and runx1w84x/+ were previously described (26, 31-268 
36). 269 
 270 
Mouse 129S1/Svlmj and C57BL6/J strains were bred and maintained according to 271 
institutional animal care and use committee guidelines at University of Pennsylvania. 272 
Generation of the murine Chd7 targeting vector and electroporation into C57BL/6J ES cells was 273 
performed by InGenious Targeting Laboratory, Ronkonkoma, NY (details available upon 274 
request). Chimeric mice were mated to 129S1/SvImj x C57BL6/J F1 mice, and progeny 275 
backcrossed to C57BL/6J mice for 6 generations.  Primers for Chd7 genotyping were JMH61: 276 
AAAATGTGGATCTCTCTCCAAACT, JMH65:TTATTTTCTTGAGACAAGGCCTCAC, JMH66: 277 
GGTAACACAC TCCTTTAAACCCAGA. Vav1-Cre mice were provided by Thomas Graf (37). 278 
 15 
Runx1+/- (Runx1tm1Spe), Cbfb+/M (Cbfbtm1lhc), Cdh5-Cre, and -actin-Cre mice were described 279 
previously (28, 38-40). Both male and female animals were used for experiments.  280 
 281 
Embryo staining and microscopy. 282 
Whole mount in situ hybridization on zebrafish embryos fixed in 4% paraformaldehyde 283 
was performed as described previously (41) with a minimum of two independent replicates 284 
performed for each staining. Ratios represent number of embryos with indicated phenotype/total 285 
number scored. Stained embryos were imaged using a Nikon stereoscope with a Nikon Coolpix 286 
4500 camera or Zeiss camera. Embryos mounted in glycerol were imaged on a Nikon E600 287 
compound microscope. Confocal imaging was performed on a Zeiss spinning disk confocal 288 
microscope using Volocity (PerkinElmer) or ZEN (ZEISS) software for image acquisition. 289 
 290 
Whole mount immunostaining of mouse embryos were processed as described (15). 291 
Primary antibodies used were rabbit anti-mouse CD117 (Thermo Fisher Scientific Cat# 14-1171-292 
82,, RRID:AB_467433), rat anti-mouse CD31 (BD Biosciences Cat# 550274, RRID:AB_393571), and 293 
rabbit anti-human/mouse RUNX1 (Abcam Cat# 2593-1, RRID:AB_1580795). Secondary antibodies 294 
were purchased from Invitrogen: goat anti-rat Alexa Fluor 647 (Thermo Fisher Scientific Cat# A-295 
21247, RRID:AB_141778), goat-anti rat Alexa Fluor 555 (Thermo Fisher Scientific Cat# A-21434, 296 
RRID:AB_2535855), and goat anti-rabbit Alexa Fluor 488 (Thermo Fisher Scientific Cat# A-11006, 297 
RRID:AB_2534074). Images were collected on a Zeiss LSM 710 confocal microscope equipped 298 
with 488-, 543- and 633-nm wavelengths and a 20x immersion objective (Plan-Apochromat 299 
25x/0.8 NA). Data were acquired using Zeiss ZEN 2011 and processed using FIJI software (42), 300 
LOCI Bio-Formats Importer (http://dev.loci.wisc.edu/fiji/) and the cell counter plugin (version 29 301 
February 2008, Kurt De Vos, http://rsb.info.nih.gov/ij/plugins/cell-counter.html). To count 302 
hematopoietic clusters, 2 to 3 micron thick Z-sections were collected.  303 
 304 
 16 
Transplantation Assays. 305 
 Limiting dilution transplantations were performed using total bone marrow cells and 306 
sorted CD48-CD150+LinnegSca1+Kit+ cells from Chd7f/f or Chd7f/f;Vav1-Cre mice (C57BL/6J), 307 
along with 2x105 total bone marrow competitor cells (129S1/SvlmJ x B6.SJL-308 
PtprcaPepCb/BoYJ F1) into 9 Gy lethally irradiated recipients (B6.SJL-Ptprca Pepcb/BoyJ (B6-309 
LY5.2/Cr)). To purify CD48-CD150+LinnegSca1+Kit+ donor cells, bone marrow cells were 310 
lineage depleted using biotinylated antibodies to CD3, CD5, CD19, B220, Gr1, Mac1 and anti-311 
biotin MACS beads on a MACS column (Miltenyi Biotec), then stained with lineage antibodies 312 
(B220, Gr1, Mac1, CD3e, Ter119; eFlour450), Sca1 PerCP/Cy5.5, Kit APC-eFlour780, CD48 313 
APC, CD150 PE-Cy7 and sorted on a BD FACSAria.  314 
 315 
For serial transplantation, 2 x 106 total BM donor cells were transplanted into lethally 316 
irradiated B6-LY5.2/Cr recipient mice without competitors as described above. At 4 months, 2 317 
x 106 BM cells from each primary recipient were transplanted into secondary B6-LY5.2/Cr 318 
recipients. The transplant was carried out until tertiary recipients were transplanted into fourth 319 
B6-LY5.2/Cr recipients. 320 
 321 
Positive engraftment was scored three different ways: 1) ≥1% of all cell lineages in PB 322 
were donor-derived at 4 months post-transplantation; 2) ≥1% Mac1+ cells in PB were donor-323 
derived at 4 months post-transplantation; 3) ≥1% CD48-CD150+LSK cells in BM were donor-324 
derived. ELDA  (43) R statistical software was used to assess differences between paired sets 325 
of limiting dilution analyses to give the estimate of functional LT-HSC numbers. 326 
 327 
To assess response to stress, 150 mg/kg 5-fluorouracil (FU) (Sigma) was injected 328 
intravenously and HSCs were analyzed 7 days later by flow cytometry (27). 329 
 330 
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Progenitor Assays. 331 
Myeloid methylcellulose assay using bone marrow and fetal cells was described 332 
previously (44). Embryonic lymphoid T and B progenitors assays using OP9 and OP9-DL1 333 
stromal cells were performed as described (45, 46). L-Calc (Stem Cell Technologies) was used 334 
to calculate the progenitor frequencies.  335 
 336 
RNA isolation, microarray processing, and analysis. 337 
Mouse genome 1.0 arrays were used to perform microarray analysis of Chd7f/f and 338 
Chd7f/f;Vav1-Cre CD48-CD150+LSK cells. Following lineage depletion, CD48-339 
CD150+LinnegSca1+Kit+ cells were sorted directly into TRIzol LS (Ambion, 10296028). cDNAs 340 
were generated using the Nugen WT-Ovation Pico system with Exon Module 3 (Nugen, 3300 341 
and 2000-12) and were hybridized to Affymetrix Mouse 430v.2 chip (Affymetrix Mouse Gene 342 
2.0ST). Intensity CEL files were normalized with the Robust Multichip Average (RMA) algorithm. 343 
Expression value fold change cutoff was set at 2-fold and p-value set as 0.05 for Ingenuity 344 
Pathway Analysis (IPA) using default parameters. 345 
 346 
MouseGene 2.0 ST arrays were used to perform microarray analysis of LT-HSCs (CD48-347 
CD150+CD34-LSK) ST-HSCs (CD48-CD150+CD34+LSK), and MPPs (CD48+CD150-CD34+LSK) 348 
populations from 8 week old C57BL6J mice for Chd7 expression. Differentially expressed genes 349 
were assessed as those with at least a log fold expression change of 1 and an FDR based 350 
adjusted p-value of <0.1. 351 
 352 
CHD7 deletion mutants cloned in pcDNA3.1 vector (24) were used to synthesize mRNA 353 
for microinjection in zebrafish embryos. Constructs were linearized with AvrII (NEB), then 354 
purified by ethanol precipitation after phenol:chloroform extraction for mRNA synthesis using 355 





Flow cytometry. 360 
Flow cytometry was performed on BD LSRII or FACSAria, and data were analyzed with 361 
Flowjo (Tree Star Inc.). For analysis of Tg(kdrl:EGFP) embryos, embryos were manually 362 
dissociated in PBS containing Liberase (Sigma-Aldrich), then washed and filtered in 0.9X 363 
PBS/2% FBS.  364 
 365 
Monoclonal antibodies used for analysis of adult and embryonic blood cells in mice were 366 
as described above (27) with the following additions/exceptions: CD19 (BD Biosciences Cat# 367 
561738, RRID:AB_10893995), CD71 (BD Biosciences Cat# 553266, RRID:AB_394743). FACS 368 
staining of the embryonic peripheral blood was performed as described previously (47, 48). For 369 
fetal liver HSPC analysis, lineage antibodies included CD3, CD5, CD19, B220 and Gr1, but not 370 
Mac1.  371 
 372 
Cell cycle, proliferation, and apoptosis analysis. 373 
Mouse BrdU assays were performed as described previously (27). Antibodies to Ki-67 374 
(BioLegend Cat# 652405, RRID:AB_2561929) and Annexin V (Thermo Fisher Scientific Cat# 88-375 
8005-72, RRID:AB_2575162) were used to analyze proliferation and apoptosis.   376 
 377 
RT- and qPCR. 378 
Pools of 20 to 50 embryos were homogenized in TRIzol, and RNA extracts were prepared 379 
according to the manufacturer’s protocol (Life Technologies). Genomic DNA was removed with 380 
TURBO DNA-free kit (Ambion), followed by cDNA synthesis using SuperScript III First Strand 381 
synthesis kit according to the manufacturer’s protocol (Life Technologies). Primers used for RT-382 
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PCR were: chd7 ex2 forward: 5’‐GGGCACCTACTCACCAATCA‐3’, chd7 ex4 reverse: 5’- 383 
GCCTCTTTCTTGGTGCTGTT‐3’, chd7 ex3 forward: 5’-TCCCAAGACACCCAAAGAAC-3’, chd7 384 
ex5 reverse: 5’-GCCTCTTTCTTGGTGCTGTT-3’, ef1α forward: 5’-ATCTACAAATGC 385 
GGTGGAAT-3’, ef1α reverse: 5’-ATACCAGCCTCAAACTCACC-3’. qPCR was performed using 386 
SsoFast EvaGreen Supermix on a BioRad C1000 CFX-384 real-time PCR machine. qPCR 387 
primers used were: myb forward: 5’-CCGACAGAAGCCGGATGA-3’, myb reverse: 5’- 388 
TGGCACTTCGCCTCAACTG-3’, runx1 forward: 5’-CGTCTTCACAAACCCTCCTCAA-3’, and 389 
runx1 reverse: 5’-GCTTTACTGCTTCATCCGGCT-3’. ΔCt values were normalized to ef1α.  390 
 391 
Western blot and LC-MS/MS protein identification. 392 
Nuclear extracts from murine T-ALL cell line 720 (49) were incubated with protein A Dynabeads 393 
coupled with anti-CHD7 (Abcam Cat# ab31824, RRID:AB_869129), RUNX1 (Millipore Cat# PC284, 394 
RRID:AB_2254229), CBF (141.1, Speck lab), Flag (Sigma-Aldrich Cat# A2220, 395 
RRID:AB_10063035) or CHD4 (Abcam Cat# ab72418, RRID:AB_1268107) antibodies overnight at 396 
4C or at room temperature for 1 hour. 397 
 398 
For LC-MS/MS, FLAG-tagged CBF was expressed in and immunoprecipitated from extracts of 399 
the 720 T-ALL cell line (49). The CBF immunoprecipitates will contain RUNX subunits and 400 
other RUNX-CBF interacting proteins. As a control, a FLAG-tagged CBF containing two 401 
amino acid substitutions that decrease RUNX1 binding (50) was immunoprecipitated as a 402 
negative control to subtract out proteins that bound to FLAG-CBF in the absence of RUNX. 403 
Identification of protein-protein interactors was performed by excision of regions of SDS-PAGE-404 
separated immunoprecipitates, in-gel digestion and peptide shotgun sequencing as described 405 
(51). Briefly, gel regions were destained to clarity, dehydrated, digested with trypsin, extracted 406 
and analyzed by LC-MS/MS on an LTQ Orbitrap mass spectrometer. The resulting MS/MS 407 
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spectra were data searched using the SEQUEST algorithm (52) against a mouse proteome 408 
database (International Protein Index; IPI) and curated to a <1% false discovery rate (FDR) 409 
using the target-decoy strategy (53). Proteins were required to have a minimum of 3 peptides to 410 
be declared as a positive identification. 411 
 412 
ChIP-sequencing. 413 
ChIP-seq and DNase I hypersensitivity mapping in 416B cells was performed as described 414 
previously (19, 54). De novo motif analysis was performed using HOMER (55).  415 
 416 
RNA-sequencing. 417 
Transcriptional profiles of 416B cells expressing sgRNAs were analyzed using a protocol based 418 
on the Smart-Seq2 system (56) with the following modifications: pools of 75 cells expressing 419 
each sgRNA were sorted into 96-well plates containing lysis buffer, and cDNA was amplified 420 
with 13 PCR cycles. Each experimental condition was analyzed in quadruplicates. Illumina 421 
sequencing was perfomed on a HiSeq 4000 instrument. Reads were aligned against mouse 422 
reference genome GRCm38/mm10 using GSNAP, and those overlapping exons (ENSEMBL 423 
m38.81) were counted using HTSeq (57). Differential gene expression was performed using the 424 
DESeq2 package (58). 425 
 426 
Cell lines. 427 
To generate CBFB-MYH11 expressing cells, the mouse myeloid progenitor cell line 416B was 428 
co-transfected with: 1) a plasmid containing the tetracycline transcription silencer (tTS), the 429 
tetracycline transactivator (rtTA) and blasticidin resistance under the control of a Ef1α promoter 430 
and 2) a plasmid containing the entire Cbfb-Myh11 type A cDNA in frame with an F2A element 431 
and mCherry protein under the control of a tetracycline responsive element. As control, cells 432 
were alternatively transfected with a plasmid lacking the Cbfb-Myh11 cDNA. Transposase 433 
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PL623 (59) (kindly donated by Pentao Liu, Sanger Institute, Cambridge) was also transiently 434 
expressed to promote simultaneous stable integration of the constructs. Plasmids were 435 
transfected into 416B cells by electroporation using a BioRad electroporator (220V, 900 μF). 436 
After 24 hours, cells were selected in 1 μg/ml of blasticidin (InvivoGen). After 14 days, mCherry-437 
negative single cells that did not stain with DAPI (Sigma) were sorted into 96-well plates using a 438 
BD Influx sorter and cultured for typically 2 weeks. Clonal cultures were then tested for induction 439 
and expression levels of Cbfb-Myh11 using 1μg/ml of doxycycline. Induction of Cbfb-Myh11 for 440 
ChIP experiments, performed in replicate, was confirmed by flow cytometry for mCherry 441 
expression on a BD Fortessa. 442 
 443 
416B cells expressing Cas9 protein were obtained by transduction with pKLV2-EF1a-Cas9Bsd-444 
W lentivirus (Addgene #68343) and selected with 10 μg/ml of blasticidin (InvivoGen). Three 445 
different Chd7 and one Runx1 sgRNAs were cloned into the Perturb-seq GBC library backbone 446 
(Addgene #85968), and lentivirally transduced BFP+7AAD- cells were sorted after 4 days by flow 447 
cytometry for RNA-seq or genotyping. Efficiency of CRISPR editing was confirmed by high-448 
throughput sequencing of genomic DNA from 2x105 cells. Targeting sgRNAs sequences were: 449 
Chd7 sgRNA1 – AGACGCCAATCCGTTCCCG, Chd7 sgRNA2 – 450 
TGGTACCTGAACGGCCCGG, Chd7 sgRNA3 – GACATGCCCATAAACGAACG, Runx1 451 
sgRNA1 – GCGCACTAGCTCGCCAGGG. 452 
 453 
All cell lines were tested negative for mycoplasma contamination. 454 
 455 
Statistics. 456 
Quantitative data is shown as mean  s.d. with P values calculated using unpaired two-tailed 457 
Student’s t-test or analysis of variance (ANOVA). No statistical method was used to 458 
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predetermine sample size. The experiments were not randomized. The investigators were not 459 
blinded to allocation during experiments and outcome assessment. 460 
 461 
Data Availability. 462 
Genomic and microarray data are deposited in Gene Expression Omnibus (GEO) under the 463 
following accession numbers: GSE84136, GSE83956. 464 
 465 
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Figure 1. Chd7 negatively regulates embryonic hematopoiesis. A, Chd7 knockdown increases 
expression of hematopoietic mesodermal precursor, primitive erythroid and myeloid but not 
early mesoderm genes. Representative embryos for whole mount in situ hybridization are 
shown, with additional genes shown in  Appendix, Fig. S2. Regions of blood development are 
highlighted in red in the embryo schematic. Red arrows and arrowheads, increase. Grey arrows, 
no change. Scale bars = 50 μm. Replicates: 2. B, Chd7 knockdown increases expression of 
definitive HSPC and definitive myeloid and erythroid genes. Same descriptions as in panel a. C, 
Chd7 knockdown in Tg(myb:EGFP) embryos increases EGFP+ cells in the dorsal aorta (DA) 
and tail region (left), quantified in graph (right) (n=53-55). Representative embryos shown from 
3 independent replicates. D, Chd7 deletion in mice increases Runx1+CD31+Kit+ hematopoietic 
clusters detected by confocal imaging of E10.5 Chd7+/+, Chd7+/-, and Chd7f/f; Cdh5-Cre AGM 
regions. Representative clusters shown. i, one somite pair (sp) area; ii, individual cluster. E, 
Quantification of data from panel D (n=7-13). One-way ANOVA, Dunnett’s multiple comparison 
test; # = comparator. F, Increased number of burst forming unit–erythroid (BFU-E) and 
granulocyte/monocyte progenitors (CFU-GM) in E10.5 Chd7+/- yolk sacs (n=8-14). GEMM, 
granulocyte/erythrocyte/monocyte/megakaryocyte progenitors. G, Reduced number of lymphoid 
progenitors in E10.5 Chd7+/- embryos (n=10-12). A+U+V =AGM, umbilical and vitelline arteries. 
H, Left: the number of erythroid progenitors (EryP) in the yolk sac of Chd7f/f;Cdh5-Cre embryos 
is not altered (n=14-15). Right: Both Chd7f alleles were deleted in 65% of the colonies, and one 
allele was deleted in 27% of the colonies, thus Cdh5-Cre was active in the majority of EryP or 
their precursors (n=colonies from 6-8 yolk sacs). All graphs show mean ± s.d., unpaired two-
tailed t-test unless otherwise specified. 
 
Figure 2. CHD7 regulates hematopoiesis cell autonomously. A, Chd7 deficiency does not 
affect phenotypic LT-HSCs. Flow cytometry of LT-HSCs (CD48-CD150+), MPPs (CD48-CD150-
), and HPC-1s (CD48+CD150-) from LinnegSca1+Kit+ (LSK) bone marrow populations (left), 
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quantified in bar graph (right) (n=6-7). Mean ± s.d., unpaired two-tailed t-test. B, Schematic 
diagram of mouse limiting dilution transplantation experiments. C, The frequency of functional 
CHD7 deficient LT-HSCs was increased 2-fold in whole BM (left) and in purified CD48-
CD150+LSK cells (right) when ≥1% donor contribution to Mac1+ PB was scored at 4 months. 
LT-HSC frequency was calculated by ELDA (n=7-14 recipients per dose). D, Loss of CHD7 
increases multilineage hematopoiesis. The top functional categories for genes upregulated in 
CHD7 deficient mouse LT-HSCs were enriched for hematopoietic related functions by IPA. 
Clusters of individual functional gene annotations (squares) belonging to each category are 
labeled numerically. Replicates: 4. E, Heatmap of representative lineage specific genes 
upregulated in CHD7 deficient CD48-CD150+LSK cells. 
 
Figure 3. CHD7 cooperates with hematopoietic transcription factors to regulate 
hematopoiesis. A, CHD7 binding distribution in the murine 416B HPC cell line by ChIP-seq. 
Replicates: 2. B, Gene track of CHD7 binding overlaps with DNaseI hypersensitive sites at the 
Tal1 gene. C, Overlap of CHD7 binding and DNaseI hypersensitive sites. D, Overlap of CHD7 
binding and hematopoietic transcription factors. E, CHD7 binding sites are highly enriched for 
Ets, Runx, and Gata motifs by HOMER motif analysis. F, CHD7 binding is selectively lost from 
genomic regions where RUNX1 binding is attenuated by CBFB-MYH11. CBFB-MYH11 
expression was induced in myeloid progenitor cells by doxycycline (Dox). RUNX1 occupancy 
in a i) control clone and ii) CBFB-MYH11 expressing clone. Loss of CHD7 occupancy is iii) 
higher in regions of >4-fold RUNX1 occupancy loss and iv) minimally changed in regions of 
<2-fold RUNX1 occupancy loss. Black dotted line, no change (n.c.). Grey line, 2-fold change. 
Red line, 4-fold change. Replicate experiment shown in  Appendix, Fig. S4B. G, Gene tracks 
showing loss of RUNX1 and CHD7 binding to Evi5 (red arrows) in Dox induced CBFB-MYH11 
expressing cells.  
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Figure 4. CHD7 interacts with Runx1 and restrains RUNX1 activity. A, Scheme for identifying 
RUNX1-CBF interacting proteins in a murine T-ALL cell line. FLAG-tagged CBF containing 
two amino acid substitutions (red stars) that decrease RUNX1 binding was used as a negative 
control. B, CHD7 co-immunoprecipitates RUNX1-CBFβ but not CHD4 in murine T-ALL cells. I, 
input; S, depleted supernatant following immunoprecipitation; IP, immunoprecipitate. C, 
Deletions impinging on the RUNX1 activation domain decrease the interaction between RUNX1 
and CHD7. CHD7 was immunoprecipitated, and Western blots probed with antibodies to CHD7 
or FLAG. F-RUNX1, FLAG-RUNX1; ∆ deleted amino acids; F, vector expressing FLAG alone. 
Arrows indicate CHD7 (top panel) or full length and internally deleted RUNX1 proteins (bottom 
panel). D, C-terminal RUNX1 deletions. E, Summary of RUNX1 mapping experiments. RD, DNA 
and CBF-binding Runt domain; AD, transactivation domain; ID, inhibitory domain. F, 
Expression of hCHD7 but not the catalytically dead mutant hCHD7K999R in zebrafish embryos 
reduces myb expression in the CHT by whole mount in situ hybridization. Representative 
embryos shown. Blue arrows, decrease. Grey arrows, no change. Scale bars = 50 μm. 
Replicates: 2. G, Mutation mapping of hCHD7 domains show the ATPase/helicase domain is 
required to suppress myb and runx1 expression in the CHT. Same descriptions as in panel F. H, 
Summary of hCHD7 mapping experiments. FL, full length. CD, chromodomain. HD, 
ATPase/helicase domain. SL/SD/BD, SLIDE/SANT/BRK domains. y, yes; n, no. Quantification 
of results from panels F, G are in  Appendix, Fig. S2B. 
 
Figure 5. CHD7 interacts genetically with RUNX1 to regulate hematopoiesis. A, Chd7 and 
Runx1 interact genetically to repress myelopoiesis in the spleen of adult mice by flow cytometric 
analysis (n=4). B, Restoration of primitive erythrocyte maturation with Chd7 deletion in CbfbM 
embryos with peripheral blood analysis by flow cytometry (n=6-42). Representative plots shown. 
Simplified genotypes are: Chd7+/- = Chd7+/f;β-actin-Cre, Chd7-/- = Chd7f/f;-actin-Cre, Cbfb+/M = 
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Cbfb+/MYH11;-actin-Cre. C, Chd7 or Runx1 deletion partially restores normal maturation of 
primitive erythrocytes in E10.5 embryos expressing the dominant neomorphic Cbfb-MYH11 
allele (CbfbM). All values were significantly different as compared to Cbfb+/M. ANOVA and 
Dunnett’s multiple comparison test. D, Expansion of myb+ HSPCs in chd7 morphant (MO) 
embryos is suppressed in runx1w84x mutants expressing truncated Runx1. Whole mount in situ 
hybridization of representative embryos shown, with phenotypic results quantified in bar graph 
(right). *p < 0.01 by Chi-square test. Red arrows, increase. Blue arrows, decrease. Scale bar = 
50 μm. Replicates: 2. E, Overexpression of hCHD7 suppresses the expansion of myb+ HSPCs 
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1. Hematological system development and function
2. Inflammatory response
3. Cell death and survival
4. Tissue morphology
5. Cellular growth and proliferation
6. Organismal injury and abnormalities
7. Immune cell trafficking
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